$UPXI

UPEXI, INC. (UPXI): Entry into a Material Definitive Agreement

UPEXI, INC. (UPXI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 3 upxi_ex101.htm SECURITIES PURCHASE AGREEMENT upxi_ex101.htm EXHIBIT 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of ______________, between Upexi, Inc., a Delaware corporation (the “ Company ”), and the purchaser

Original reporting
Published Jun 24, 2026, 8:37 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 24, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$UPXI
Neutral
medium confidence
Mentioned
$UPXI
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$UPXINeutralMed
01

Why it matters

The disclosed transaction economics (secured convertible note principal and purchase price paid via note retirement) are likely to drive trading around dilution/convertible overhang and financing risk, especially for microcaps.

02

Market read

Traders can reassess near-term dilution and capital-structure risk based on the newly disclosed financing terms in today’s 8-K.

03

What to watch

Key missing terms in the excerpt—conversion price/discount, maturity, warrant coverage, and use of proceeds—can materially change dilution and risk pricing versus what traders infer from headline principal amounts.

Relevance 6/10Novelty 7/10Timing: after-hours/filing today (2026-06-24) for a new securities purchase agreement

Background

The article is an SEC Form 8-K describing entry into a material definitive agreement and unregistered equity issuance, with an attached securities purchase agreement.

Company-level read

Ticker impact

$UPXINeutralMedium confidence
Context

Upexi filed an 8-K for a material definitive securities purchase agreement, including a $35.96M secured convertible note and $19.54M purchase price via note retirement.

Expected impact

Near-term volatility possible as traders price dilution/convertible overhang; direction depends on discount, conversion terms, and investor identity (not fully shown in excerpt).

Evidence & confidence

This is a primary SEC 8-K disclosure with concrete transaction economics (note principal and purchase price), but the excerpt cuts off key terms (e.g., conversion mechanics, warrants, proceeds use), limiting precision on dilution impact.

Market effects

Microcap/small-cap financing activity can signal ongoing capital needs; read-across to other highly levered issuers is limited without sector-specific context.

Primarily US microcap sentiment; limited broader regional spillover expected.

Low global relevance; transaction appears company-specific and US-focused under SEC filings.

Counterpoint

If the note is being retired at a favorable structure (e.g., reducing future interest/overhang), the deal could be less dilutive than feared.

Key entities

  • Upexi, Inc.

    Subject of the 8-K; entered into a securities purchase agreement involving a secured convertible note and pre-funded warrants.

  • Securities Purchase Agreement (Exhibit 10.1)

    Defines the terms of the unregistered sale and the transaction mechanics, including per-share purchase price and note retirement.

Related articles

$UPXIMed

Upexi Partners with Blueprint to Stake Solana Treasury Assets

Upexi, Inc. (NASDAQ: UPXI) said it partnered with Blueprint, an institutional Solana staking/infrastructure affiliate of Hivemind Capital Partners, to stake a portion of its Solana (SOL) holdings using Blueprint’s institutional Solana validator. Upexi said it aims to grow its SOL treasury and support Solana network decentralization; it reported holding over 2 million SOL.

$TEVAMed

Teva Transitions To Direct Listing On NYSE

Teva Pharmaceutical (TEVA) will transition to direct listing on NYSE, continuing to trade on NYSE and TASE. The move is part of its Pivot to Growth strategy. The company reported 40% revenue growth in 2025, with 2026 revenues estimated at $3.7B. TEVA closed Friday at $37.09, up 2.04%, and Monday at $38.72, up 4.39%.

$ASNDMed

Ascendis Unveils $400 Mln Buyback; Regains TransCon Rights From Novo Nordisk

Ascendis Pharma (ASND) authorized a $400M share buyback program and regained exclusive rights to TransCon-based products in metabolic and cardiovascular diseases from Novo Nordisk. The company plans to develop new programs, including TransCon Semaglutide for obesity and type 2 diabetes. In Q2 2026, ASND reported a net profit of €207M, up from a €39M loss a year prior, with revenue increasing to €339.29M from €158.04M.

$PBFHighAI 9/10

PBF Energy Announces Pricing of $500 Million of 0% Exchangeable Notes due 2032

PBF Energy's subsidiary priced $500M in 0% exchangeable notes due 2032, with an option for $50M more. Notes are senior, unsecured, and guaranteed by certain subsidiaries. They can be exchanged for cash, stock, or a mix, with an initial exchange rate of 10.3306 shares per $1,000. The offering is expected to close September 17, 2026, with net proceeds estimated at $485M ($533.6M if the option is fully exercised).

$KDPMedAI 8/10

Keurig Dr Pepper breakup could reveal the stronger business

Keurig Dr Pepper (KDP) plans to split into two publicly traded companies by early 2027. Bank of America (BofA) estimates the beverage division could be worth $31 per share, while the coffee division could be worth $7 per share. BofA maintains a Buy rating on KDP with a $38 price target, citing the potential value unlock from the separation. The beverage business has shown strong growth, with Dr Pepper becoming a key driver. KDP aims to reduce debt to maintain investment-grade ratings before the